Table 3.
VEGF and VEGFR2 SNPs and the Frequency and Duration of Hypertension During Treatment
| SNP/Genotypea | Frequency of HTN During Treatment | Duration of HTN as a % of the Total Treatment Period | ||||
|---|---|---|---|---|---|---|
| N | N (%) | Pb | Median | Range | Pc | |
| −2578 | ||||||
| AA | 11 | 11 (100%) | 33.8% | 2.6%–100% | ||
| CA | 38 | 34 (89%) | 15.3% | 0%–74.8% | ||
| CC | 14 | 10 (71%) | .03 | 11.1% | 0%–100% | .22 |
| −1498 | ||||||
| CC | 14 | 14 (100%) | 19.8% | 2.6%–100% | ||
| TC | 34 | 30 (88%) | 17.0% | 0%–74.8% | ||
| TT | 15 | 11 (73%) | .03 | 11.6% | 0%–100% | .31 |
| −1154 | ||||||
| AA | 35 | 32 (91%) | 20.4% | 0%–100% | ||
| AG/GA | 26 | 22 (85%) | 12.2% | 0%–85.4% | ||
| GG | 2 | 1 (50%) | .14/.45d,e | 23.4% | 0%–46.8% | .87/.88e |
| −634 | ||||||
| GG | 36 | 34 (94%) | 27.2% | 0%–100% | ||
| CG/GC | 21 | 17 (81%) | 10.2% | 0%–71.6% | ||
| CC | 6 | 4 (67%) | .03 | 8.9% | 0%–28.1% | .01 |
| 936 | ||||||
| TT | 1 | 1 (100%) | 85.4% | — | ||
| CT/TC | 12 | 11 (92%) | 21.3% | 0%–71.3% | ||
| CC | 50 | 43 (86%) | .52/1.0d,f | 14.0% | 0%–100% | .27/.61f |
| 889 | ||||||
| GG | 51 | 45 (88%) | 14.3% | 0–100% | ||
| GA | 12 | 10 (83%) | .14d | 21.3% | 0–100% | .44 |
| 1416 | ||||||
| TT | 3 | 3 (100%) | 2.7% | 0–42.4% | ||
| AT | 18 | 15 (83%) | 12.5% | 0–100% | ||
| AA | 42 | 37 (88%) | .98/.29d,g | 21.4% | 0–100% | .30/.34g |
Abbreviations: HTN, hypertension; SNP, single nucleotide polymorphism.
a
Predicted genotype from Haploview used if missing: −2578, n = 3; −1498, n = 0; −1154, n = 17; −634, n = 0; −936, n = 7; 889, n = 7; 1416, n = 8.
b
Cochran-Armitage trend test unless otherwise noted.
c
From linear regression model with the specified SNP as the only independent variable unless otherwise noted.
d
Fisher’s exact test.
e
Second P value compares AA to other genotypes.
f
Second P value compares CC to other genotypes.
g
Second P value compares AA to other genotypes.